About
Corrixr develops targeted genetic medicines that disable NRF2 in lung, head & neck, and esophageal squamous cell cancers to improve treatment efficacy while minimizing systemic toxicity.
Explore Corrixr's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.